Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026)
Absci (ABSI) posted Net Income towards Common Stockholders of -$29.6 million for Q1 2026, little changed sequentially from -$29.6 million in Q4 2025, and down 12.35% YoY from -$33.8 million in Q1 2025.
Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Absci has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$29.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 12.35% year-over-year to -$29.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.4 million (down 10.2% YoY) and the FY2025 annual result came in at -$115.2 million, down 11.71% from the prior year.
- Net Income towards Common Stockholders held at -$29.6 million in Q1 2026 per ABSI's latest filing, from -$29.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$19.5 million in Q4 2022 and troughed at -$41.7 million in Q2 2023.
- A 5-year average of -$27.3 million and a median of -$27.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 146.67% in 2022, then jumped 40.61% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$19.5 million in 2022, then retreated by 20.92% to -$23.5 million in 2023, then decreased by 23.1% to -$29.0 million in 2024, then decreased by 2.0% to -$29.6 million in 2025, then retreated by 0.13% to -$29.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$29.6 million, -$29.6 million, and -$28.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | -33.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.21 Mn |
| Mar 31, 2026 | -29.60 Mn |
| Dec 31, 2025 | -29.56 Mn |
| Sep 30, 2025 | -28.71 Mn |
| Jun 30, 2025 | -30.57 Mn |
| Mar 31, 2025 | -26.35 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -27.40 Mn |
| Jun 30, 2024 | -24.75 Mn |
| Mar 31, 2024 | -21.98 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -21.99 Mn |
| Jun 30, 2023 | -41.67 Mn |
| Mar 31, 2023 | -23.36 Mn |
| Dec 31, 2022 | -19.47 Mn |
| Sep 30, 2022 | -27.26 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -29.49 Mn |
| Dec 31, 2021 | -25.17 Mn |
| Sep 30, 2021 | -23.88 Mn |